Evidence map›Paper›PMID 23386199›Full record

ArticleEuropean journal of immunology2013

Sculpting MHC class II-restricted self and non-self peptidome by the class I Ag-processing machinery and its impact on Th-cell responses.

Charles T Spencer, Srdjan M Dragovic, Stephanie B Conant, Jennifer J Gray, Mu Zheng, Parimal Samir, Xinnan Niu, Magdalini Moutaftsi, Luc Van Kaer, Alessandro Sette and 2 more

Abstract read
In one paragraph

Article in European journal of immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Associations betweenBioMed research international · 2021
    Pooled it
  2. Review
  3. The Human Leukocyte Antigen (HLA)-B27 PeptidomeMolecular & cellular proteomics : MCP · 2017
    Article
  4. The melting pot of the MHC II peptidome.Current opinion in immunology · 2016
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Charles T SpencerDepartment of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA. ctspencer@utep.edu
Srdjan M Dragovic
Stephanie B Conant
Jennifer J Gray
Mu Zheng
Parimal Samir
Xinnan Niu
Magdalini Moutaftsi
Luc Van Kaer
Alessandro Sette
Andrew J Link
Sebastian Joyce
Vanderbilt University · USLa Jolla Institute for Immunology · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
TCCG12MD007592 · NIMHD · UNIVERSITY OF TEXAS EL PASO · PI KIRKEN, ROBERT A. · 2012 to 2018
$19.4M
Immunobiology of Blood and Vascular Systems Training ProgramT32HL069765 · NHLBI · VANDERBILT UNIVERSITY · PI HAWIGER, JACK J · 2002 to 2016
$6.5M
MOLECULAR IMMUNOLOGY OF MINOR HISTOCOMPATIBILITY ANTIGENR01HL054977 · NHLBI · VANDERBILT UNIVERSITY · PI JOYCE, SEBASTIAN · 1995 to 2009
$2.6M
Processing and Presentation of Minor Histocompatibility Antigens that Cause GvHDR01HL121139 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOYCE, SEBASTIAN · 2014 to 2017
$1.6M
NCI NIH HHS CA068485NCI NIH HHS P30 CA068485NHLBI NIH HHS HL054977NHLBI NIH HHS HL069765NHLBI NIH HHS R01 HL054977NHLBI NIH HHS R01 HL121139NHLBI NIH HHS T32 HL069765NIAID NIH HHS AI040024NIAID NIH HHS N01 AI040024NIAID NIH HHS N01 AI040079NIDDK NIH HHS DK058404NIDDK NIH HHS P30 DK058404NIMHD NIH HHS G12MD007592
6 · The paper itself

Abstract

It is generally assumed that the MHC class I antigen (Ag)-processing (CAP) machinery - which supplies peptides for presentation by class I molecules - plays no role in class II-restricted presentation of cytoplasmic Ags. In striking contrast to this assumption, we previously reported that proteasome inhibition, TAP deficiency or ERAAP deficiency led to dramatically altered T helper (Th)-cell responses to allograft (HY) and microbial (Listeria monocytogenes) Ags. Herein, we tested whether altered Ag processing and presentation, altered CD4(+) T-cell repertoire, or both underlay the above finding. We found that TAP deficiency and ERAAP deficiency dramatically altered the quality of class II-associated self peptides suggesting that the CAP machinery impacts class II-restricted Ag processing and presentation. Consistent with altered self peptidomes, the CD4(+) T-cell receptor repertoire of mice deficient in the CAP machinery substantially differed from that of WT animals resulting in altered CD4(+) T-cell Ag recognition patterns. These data suggest that TAP and ERAAP sculpt the class II-restricted peptidome, impacting the CD4(+) T-cell repertoire, and ultimately altering Th-cell responses. Together with our previous findings, these data suggest multiple CAP machinery components sequester or degrade MHC class II-restricted epitopes that would otherwise be capable of eliciting functional Th-cell responses.

Indexed as

Antigen PresentationAmino Acid SequenceAnimalsAntigen-Presenting CellsAntigens, LyEpitopesHistocompatibility Antigens Class IHistocompatibility Antigens Class IILeucyl AminopeptidaseMembrane ProteinsMiceMice, KnockoutMolecular Sequence DataPeptide FragmentsProteomicsSequence Analysis, ProteinAntigens, LyEpitopesHistocompatibility Antigens Class IHistocompatibility Antigens Class IILeucyl AminopeptidaseLy6a protein, mouseMembrane ProteinsPeptide Fragmentspuromycin-insensitive leucyl-specific aminopeptidase

Identifiers

PMID23386199
PMCPMC3798073
OpenAlexW1482169682

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.